Compare XTNT & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | YI |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 57.1M |
| IPO Year | 2009 | 2018 |
| Metric | XTNT | YI |
|---|---|---|
| Price | $0.47 | $5.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 150.9K | 15.4K |
| Earning Date | 05-08-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,337,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $2.48 |
| 52 Week High | $0.95 | $11.17 |
| Indicator | XTNT | YI |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 36.20 |
| Support Level | $0.44 | $4.31 |
| Resistance Level | $0.67 | $7.18 |
| Average True Range (ATR) | 0.03 | 0.47 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 19.73 | 34.44 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.